Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
Study identifier:LB-001LT
ClinicalTrials.gov identifier:NCT05506254
EudraCT identifier:N/A
CTIS identifier:N/A
Recruitment Complete
Official Title
A Long-term Follow-up Study of Patients in LogicBio Clinical Trials for Methylmalonic Acidemia Characterized by MMUT Mutations Who Received hLB-001
Medical condition
Methylmalonic Acidemia
Phase
-
Healthy volunteers
No
Study drug
hLB-001
Sex
All
Actual Enrollment
4
Study type
Observational
Age
N/A
Date
Study Start Date: 20 Jul 2022
Estimated Primary Completion Date: 31 Dec 2037
Estimated Study Completion Date: 31 Dec 2037
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Dec 2024 by LogicBio Therapeutics, Inc.
Sponsors
LogicBio Therapeutics, Inc.
Collaborators
Alexion Pharmaceuticals, Inc.
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients who have previously received hLB-001 | - |
